TfR mAb-Cross-Linked Rituximab/MTX-PEG-PLL-PLGA Drug-Loaded Nanoparticles Enhance Anticancer Action in B Lymphocytes

Figure 2

UVA sensitivity and stability of Rituximab- (a), MTX- (b), or TfR mAb- (c) loaded nanoparticles. (d) The drug loading content (DLC) and drug loading efficiency (DLE) of Rituximab and MTX and the modification rate of TfR mAb in TfR mAb/Rituximab/MTX-PEG-PLL-PLGA nanoparticles.

(a)

(b)

(c)

(d)